New search | Conferencedetail
mail
Print view
 
 

12th Alzheimer's and Parkinson's Drug Development Summit

Evvnt Promotion / evvnt
Archive
-
23.04.2024 - 25.04.2024  Hilton Boston Logan Airport, One Hotel Drive, 02128 Boston, Massachusetts, USA
Time: 9:00 AM - 5:00 PM
 
Conference themes
After a 17-year hiatus in drug approvals for neurodegeneration, disease-modifying drugs for AD have finally broken the ice. With Lecanemab's clinically proven 30% reduction in cognitive decline receiving the green light from the FDA and PMDA and Eli Lilly's Donanemab hot on their heels for approval, 58 new trials entering the pipeline this year, and the alpha-synuclein self-seeding assay changing the game for PD drug development.
Professional congress organizer (PCO)
Hanson Wade
Notes
Brochure: https://go.evvnt.com/2146026-3?pid=4832

Speakers: Achim Kless, PhD, Senior Director Pain Genetics, Eli Lilly and Co., Arnon Rosenthal, Co-Founder and Chief Executive Officer, Alector Pharmaceuticals LLC, and more
 

Enquiries and Registration:

https://go.evvnt.com/2146026-2?pid=4832
Ms. Erin Thomas
 
Categories
General Medicine
Languages
English
Congress fees
USD 2999.00 - USD 5197.00
Participants expected
1000 - 1000
Organizer contact info
83 Great Titchfield Street
W1W 6RH London
United Kingdom
 
"Going International promotes access to education and training for all regardless of social, geographic and national borders."

Helix - Forschung & Beratung WiennewTreeHilfswerk AustriaCharité International AcademyÄrzte der WeltÖsterreichische Gesellschaft für Public HealthCentro per la Formazione Permanente e l'Aggiornamento del Personale del Servizio SanitarioCenter of Excellence